Effect of three B-cell inhibitors: rituximab, alemtuzumab and bortezomib on anti-A and/or anti-B titer kinetics.

Completed

• Conditions: 10038430; kidneytransplant; 10018849

• Registration Number: NL-OMON39959
• Lead Sponsor: eids Universitair Medisch Centrum

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 29 April 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 24

Inclusion Criteria

age * 18 yr
patients should be competent
have blood group A,B or O
will receive treatment with rituximab, bortezomib, alemtuzumab (prescribed by their hematologist)

Exclusion Criteria

blood group AB
having a low antiA/B titer < 1:8
treatment with IVIG or plasma in the past three months

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>The dynamics of the anti A/B titer in time of three different B cell-inhibitors<br /><br>(rituximab, bortezomib, alemtuzumab).</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>effect of blood transfusions on the anti A?B titers.</p><br>